Published on 30 Nov 2021 on Zacks via Yahoo Finance
QIAGEN N.V. QGEN and DiaSorin recently announced the receipt of FDA approval of the LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin’s automated LIAISON XS platform. QIAGEN and DiaSorin developed the LIAISON QuantiFERON-TB Gold Plus, an interferon-gamma release assay (IGRA), to provide streamlined laboratory automation for latent tuberculosis (TB) screening. QuantiFERON-TB tests for interferon-gamma generated by T-cells that have encountered TB bacteria.
The recent FDA approval for LIAISON XS platform builds on the already approved use of QuantiFERON-TB assay running on the LIAISON XL platforms in the United States since 2019. This authorization expands U.S. customers’ accessibility to automation solutions for processing QIAGEN’s blood-based test for latent TB detection and facilitates the transition from traditional tuberculin skin tests.
Strategic Significance